What is Azafaros?
Azafaros B.V. is dedicated to developing innovative therapies for patients suffering from severe rare metabolic disorders, particularly lysosomal storage disorders. Their lead clinical candidate, nizubaglustat, is an orally available azasugar that targets the central nervous system and modifies glycosphingolipid metabolism through a unique dual mode of action. The company is actively engaged in advancing clinical studies, including Phase 3 trials for conditions such as Niemann-Pick disease Type C and GM1/GM2 gangliosidoses.
How much funding has Azafaros raised?
Azafaros has raised a total of $27.4M across 1 funding round:
Series A
$27.4M
Series A (2020): $27.4M with participation from BioGeneration Ventures B.V, BioMedPartners, and Forbion
Key Investors in Azafaros
BioGeneration Ventures B.V
BioGeneration Ventures B.V. is an investor in Azafaros, likely focusing on early-stage biotechnology companies with innovative therapeutic approaches.
BioMedPartners
BioMed Partners is an independent venture capital firm based in Basel, Switzerland, specializing in early-stage biotech companies in Europe. They focus on assets, technology platforms, and strong entrepreneurial teams.
Forbion
Forbion is a prominent European venture capital firm that invests in life sciences companies, particularly those developing innovative therapeutics.
What's next for Azafaros?
With its recent major strategic investment, Azafaros is poised to accelerate its clinical development pipeline. The company's focus on advancing nizubaglustat through Phase 3 trials for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses indicates a strategic push towards regulatory approval and market entry. This financing will likely support expanded clinical operations, manufacturing scale-up, and further research into lysosomal storage disorders, positioning Azafaros as a key player in the rare disease therapeutic landscape.
See full Azafaros company page
